Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for delgocitinib (TBC) for the treatment of moderate to severe chronic hand eczema (CHE), including the relief of pain and pruritus (itching), in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.